OTCMKTS:SNYNF Sanofi (SNYNF) Stock Price, News & Analysis $80.91 +0.95 (+1.19%) As of 02:19 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsNews and TrendsSEC Filings About Sanofi Stock (OTCMKTS:SNYNF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sanofi alerts:Sign Up Key Stats Today's Range$79.80▼$83.5950-Day Range$79.96▼$93.4552-Week Range$79.75▼$106.34Volume1,284 shsAverage Volume28,771 shsMarket CapitalizationN/AP/E Ratio26.23Dividend Yield3.46%Price TargetN/AConsensus RatingN/A Company Overview Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its portfolio focuses on immunology, rare diseases, vaccines, specialty care and established prescription medicines, serving patients and healthcare providers in markets around the world. The company’s products include Dupixent for several inflammatory conditions, Beyfortus for the prevention of respiratory syncytial virus disease in infants, and vaccines for influenza, meningococcal disease, polio and other conditions. Sanofi also offers treatments across areas such as diabetes, cardiovascular disease, oncology and rare diseases. Sanofi traces its roots to French pharmaceutical businesses established during the 20th century and became Sanofi-Aventis following the 2004 acquisition of Aventis. The company adopted the Sanofi name in 2011. Its global operations span research, manufacturing and commercial activities across North America, Europe, Asia and other international markets. Sanofi is led by Chief Executive Officer Paul Hudson.AI Generated. May Contain Errors. Read More Receive SNYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNYNF Stock News HeadlinesDeutsche Bank Sticks to Its Buy Rating for Sanofi (SNYNF)September 15, 2026 | theglobeandmail.comRBC Capital Initiates a Hold Rating on Sanofi (SNYNF)September 9, 2026 | theglobeandmail.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.September 28 at 1:00 AM | Monument Traders Alliance (Ad)Sanofi (SNYNF) Gets a Hold from UBSAugust 20, 2026 | theglobeandmail.comAnalysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Ligand Pharma (LGND) and Exelixis (EXEL)August 12, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Qiagen (QGEN) and Sanofi (OtherSNYNF)August 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Align Tech (ALGN)July 26, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Ocular Therapeutix (OCUL)June 24, 2026 | theglobeandmail.comSee More Headlines SNYNF Stock Analysis - Frequently Asked Questions How have SNYNF shares performed this year? Sanofi's stock was trading at $97.2950 at the beginning of 2026. Since then, SNYNF shares have decreased by 16.8% and is now trading at $80.91. How do I buy shares of Sanofi? Shares of SNYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/28/2026Next Earnings (Estimated)10/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:SNYNF CIK1121404 Webwww.sanofi.com Phone(315) 377-4000FaxN/AEmployees91,600Year Founded2004Profitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio26.23 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:SNYNF) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNYNF Stock Alerts